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ABSTRACT
Background: Monocarboxylate transporters (MCTs) are cell membrane 
proteins which transport pyruvate, lactate and ketone bodies across the plasma 
membrane. MCTs are activated in various cancers, but their expression in esophageal 
adenocarcinoma is not known. The present study was conducted to elucidate the 
expression of MCTs in esophageal adenocarcinoma and its precursor lesions. 
Results: Cytoplasmic MCT1, MCT4 and MTCO1 expression linearly increased from 
normal epithelium to Barrett's mucosa to dysplasia and cancer. Low cytoplasmic MCT1 
expression associated with high T-class (P < 0.01), positive lymph node metastases 
(P < 0.05), positive distant metastases (P < 0.01) and high tumor stage (P < 0.01).  
High cytoplasmic MCT4 expression correlated significantly with positive distant 
metastases (P < 0.05). Both low MCT1 and high MCT4 histoscore predicted survival 
in univariate analysis (P < 0.01).  MCT4 histoscore predicted survival in multivariate 
analysis (P = 0.043; HR 1.8 95%CI 1.0–3.1). MTCO1 expression was not correlated 
to clinicopathological variables or survival.
Materials and Methods: MCT1, MCT4 and mitochondrial cytochrome c oxidase 
(MTCO1) expression were determined with immunohistochemistry in esophageal 
specimens from 129 patients with columnar dysplasia or adenocarcinoma. Specimens 
including normal esophagus (n = 88), gastric (n = 67) or intestinal metaplasia 
(n = 51), low-grade (n = 42), high-grade dysplasia (n = 37) and esophageal 
adenocarcinoma (n = 99) were evaluated. 
Conclusions: Major increase in markers of tumor metabolism occurs during 
carcinogenesis and progression of esophageal adenocarcinoma. MCT1 and MCT4 are 
prognostic factors in esophageal adenocarcinoma.
INTRODUCTION
The incidence of Esophageal adenocarcinoma 
is rising in the Western World, with low survival rates 
even after initially curative surgery [1]. Esophageal 
adenocarcinoma arises from Barrett’s esophagus, which 
is considered a complication of long-term esophagitis due 
to reflux disease. Barrett’s esophagus influence 2 to 7 per 
cent of adults in Western countries [2]. 
Normal cells rely on aerobic mitochondrial 
metabolism while cancer cells tend to produce energy 
through anaerobic glycolysis. Persistent activation of the 
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glycolysis can favor aggressive proliferation, invasion 
and metastatic behavior [3, 4]. Mitochondrial energy 
metabolism profile, especially oxidative phosphorylation 
and glycolysis, undergoes various changes during the 
metaplasia–dysplasia–adenocarcinoma sequence in 
Barrett’s esophagus. [5]. Monocarboxylate transporters 
(MCT) are cell membrane proteins allowing lactate to 
pass through cell membrane [6]. MCT family includes 14 
members. MCT1-4 have been demonstrated to mediate 
proton-linked bi-directional transport of monocarboxylates 
such as lactate, pyruvate, and ketone bodies across the 
plasma membrane. Increased expression of MCT1 and 
MCT4 are reported in various cancers [7].
Alterations in markers of energy metabolism are 
poorly known in esophageal adenocarcinoma. The aim 
of this study was to assess the metabolic changes during 
development of esophageal adenocarcinoma by evaluating 
MCT1, MCT4 and mitochondrial cytochrome c oxidase 
(MTCO1) in different stages of esophageal metaplasia-
dysplasia-adenocarcinoma-sequence. 
RESULTS
All available lesions were analyzed from the patient 
samples, but no more than one lesion of each type from 
a single patient. We thus analyzed 88 normal epithelial, 
67 gastric- and 51 intestinal metaplasias, 42 low-grade- 
and 37 high-grade dysplasias and 99 adenocarcinomas. 
Majority of these lesions were from cancer patients. A 
total of 23 normal epithelia, 25 gastric- and 22 intestinal 
metaplasia and 30 low-grade- and 10 high-grade 
dysplasias were analyzed from patients with dysplasia as 
the most advanced diagnosis. MCT1, MCT4 and MTCO1 
were all expressed in all studied tissues. Expression 
was predominantly cytoplasmic, and occasionally 
detected in cell membranes (Figure 1). Distribution of 
immunostaining was diffuse throughout the epithelium, 
except in normal squamous epithelium, where basal 
staining was observed. 
MCT 1, MCT4 and MTCO1 expression in non-
dysplastic lesions
Normal epithelium showed weakest cytoplasmic 
expression in all studied markers. Cytoplasmic expression 
of MCT4 and MTCO1 was significantly higher in 
metaplastic cells compared to normal epithelium. 
Cytoplasmic expression of MCT1 was higher in intestinal 
metaplasia compared to normal squamous epithelium. 
MCT1 and MCT4 expression in the subepithelial stroma 
was significantly higher in metaplasia than in normal 
epithelium. MTCO1 expression was similar in both 
normal and metaplastic epithelial stroma. Histoscores 
for MCT1, MCT4 and MTCO1 in different lesions are 
summarized in Table 1. 
MCT 1, MCT4 and MTCO1 expression in 
dysplastic lesions and adenocarcinoma
Low- and high-grade dysplasia showed higher 
cytoplasmic expression of MCT1, MCT4 and MTCO1 
than non-dysplastic lesions. MCT1 and MTCO1 
expression increased towards high-grade dysplasia 
(Table 1). Rising stromal expression was observed in 
MCT4, whereas stromal expression of MCT1 and MTCO1 
remained relatively stable.
Figure 1: Immunohistochemical staining patterns of MCTs and MTCO1. (A) Strong immunoreaction of MCT4 in both cancer 
cells and in cancer stroma. Strong diffuse expression of MCT4 can be seen. (B) Cancer showing negative staining of MCT4 in tumor stroma 
but strong MCT4 expression in tumor cells. (C) MCT4 shows strong reaction in tumor stroma and only weak diffuse expression in cancer 
cells. (D) Adenocarcinoma negative for MCT4, neither tumor stroma nor cells express MCT4. (E) Strong MCT1 expression in cancer 
cells without stromal staining (F) Cancer negative for MCT1. (G and H) Parallel figure with 2× and 10× magnifications showing strong 
immunoreaction for MTCO1 in glandular structures of Barrett’s dysplastic lesion and adenocarcinoma. Adenocarcinoma can be seen on the 
left, low-grade dysplasia in the middle and high-grade dysplasia on the right. (H) shows 10× magnification from adenocarcinoma in (G). 
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Adenocarcinoma showed slightly higher 
cytoplasmic expression of MCT1, MCT4 and MTCO1 
compared to dysplastic lesions. However, this difference 
was not statistically significant. Stromal MCT4 expression 
was the highest in adenocarcinoma, whereas expression of 
MCT1 and MCTO1 in tumor stroma did not significantly 
differ from other lesions. Cytoplasmic and stromal 
stainings are summarized in Table 1.
To explore the possible field-effects in the 
studied markers the expression of the studied markers 
in premalignant lesions was compared between cancer 
patients and dysplasia patients. The mean MCT1 
histoscore was significantly higher in premalignant 
lesions of patients with adjacent carcinoma compared 
to patients with dysplasia as the most advanced lesion 
(gastric metaplasia 81 vs. 39, intestinal metaplasia 131 
vs. 67 and low-grade dysplasia 148 vs. 81, all p < 0.05). 
No differences were observed in MCT4 and MTCO1 
expression between carcinoma and dysplasia patients.
MCT1, MCT4 and MTCO1 expression 
correlations with clinicopathological variables 
and cancer survival
Low cytoplasmic MCT1 expression correlated 
statistically significantly with higher T-class (P = 0.002), 
positive lymph node metastases (P = 0.039), positive 
distant metastases (P = 0.006) and higher tumor stage 
(P = 0.009, Table 2).  Low MCT1 histoscore predicted 
survival in univariate (P = 0.009, Figure 2), but not in 
multivariate analysis (data not shown).  
High cytoplasmic MCT4 expression correlated 
significantly with positive distant metastases (P = 
0.022) and large tumor size (P = 0.042, Table 2). MCT4 
Table 1: Baseline characteristics of MCT1, MCT4 and MTCO1 expression in normal esophageal 
squamous epithelium and in different esophageal lesions
histoscore histoscore statistical stroma stroma statistical
MCT1 mean 95% CI significance mean 95% CI significance
Normal epithelium 45 35–55 0.7 0.5–0.9
Gastric metaplasia 64 50–79 1.9 1.5–2.2 a
Intestinal metaplasia 101 78–125 a 1.5 1.2–1.8 a
Low-grade dysplasia 116 89–143 ab 1.8 1.4–2.2 a
High-grade dysplasia 149 117–181 ab 1.9 1.4–2.4 a
Adenocarcinoma 161 143–179 abc 1.4 1.1–1.6 a
MCT4
Normal epithelium 27 17–24 0.5 0.3–0.6
Gastric metaplasia 86 70–102 a 1.1 0.9–1.4 a
Intestinal metaplasia 86 63–109 a 1.6 1.3–1.9 a
Low-grade dysplasia 137 108  abc 2.0 1.7–2.4 ab
High-grade dysplasia 127 95–169 a 2.0 1.6–2.5 ab
Adenocarcinoma 148 127–170 abc 2.5 2.2–2.8 abc
MTCO1
Normal epithelium 41 33–48 0.7 0.5–0.8
Gastric metaplasia 107 94–120 a 1.0 0.8–1.2
Intestinal metaplasia 147 128–165 ab 1.2 09–1.48
Low-grade dysplasia 181 157–203 ab 1.3 1.0–1.6 a
High-grade dysplasia 209 182–235 abc 1.5 1.0–2.0 a
Adenocarcinoma 216 abc 1.4 1.2–1.7 a
a compared to normal epithelium, p < 0.05.
b compared to gastric metaplasia, p < 0.05.
c compared to intestinal metaplasia, p < 0.05.
Histoscore is counted by multiplying staining intensity (0–3) with the percentage of positive cells (0–100%), resulting with 
value between 0 and 300. Stromal staining was evaluated with 5 point scale (0–4). Values are presented as mean and 95% 
confidential interval (95%CI). For statistical testing One way ANOVA with Tukey in post hoc analysis was used.
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histoscore predicted survival in both univariate (P = 0.005, 
Figure 2), and in multivariate analysis (P = 0.043; HR 1.8 
95%CI 1.0–3.1, Figure 2). 
Since low cytoplasmic MCT1 and high MCT4 
expression correlated with clinicopathological 
variables and survival, we analyzed cancers with 
low MCT1 expression (histoscore ≤ 150) and high 
MCT4 expression (histoscore > 110) combined. This 
combination value showed significant correlation with 
distant metastasis (P < 0.001) and tumor stage (P = 
0.003, Table 2). The combination predicted survival in 
univariate analysis (P < 0.001, Figure 2). Multivariate 
analysis showed a borderline statistical significance for 
worse survival in MCT1-/MCT4+ cancers (P = 0.059; 
HR 1.8 95%CI 1.0–3.2). 
Cytoplasmic MTCO1 expression was not correlated 
to any of the clinicopathological variables or survival (data 
not shown).
Analysis of intensity and percentage of positive 
cells separately from histoscore
We also evaluated intensity and percentage 
of MCT1, MCT4 and MTCO1 separately without 
histoscore. Low cytoplasmic MCT1 expression correlated 
statistically significantly with higher T-class (P = 0.002), 
positive lymph node metastases (P = 0.039), positive 
distant metastases (P = 0.006) and higher tumor stage 
(P = 0.009, Table 2). Percentage of MCT1 positive cells 
did not correlate to studied clinicopathological variables 
Table 2: MCT1 and MCT4 histoscores compared to clinicopathological variables in esophageal 
adenocarcinoma
Variable n/N MCT1 histoscore, n MCT4 histoscore, n Combination of low MCT1 and high MCT4 histoscore
Low High p Low High p Others Low MCT1, high MCT4 p
T         
 T1 15/98 5 10 0.002 9 6 0.798 12 3 0.195
 T
2
14/98 4 8 8 6 10 2
 T3 53/98 29 24 25 28 36 17
 T4 16/98 15 1 8 8 8 8
Lymph nodes         
 negative 37/98 15 21 0.039 23 14 0.086 29 7 0.053
 positive 61/98 38 22 27 34 37 23
Organ metastases       
 negative 66/98 29 35 0.006 39 27 0.022 52 12 < 0.001
 positive 32/98 24 8 11 21 14 18
Grade         
 1 29/98 11 16 0.112 17 12 0.353 21 6 0.508
 2 26/98 13 13 10 16 16 10
 3 43/98 29 14 22 21 28 15
Stage         
 I 15/98 3 12 0.009 10 5 0.059 14 1 0.003
 II 37/98 18 17 20 17 27 8
 III 13/98 9 4 9 4 10 3
 IV 33/98 23 10 11 22 15 18
Tumor size         
small (< 40 mm) 39/95 20 18 0.722 25 14 0.042 30 8 0.080
large (≥ 40 mm) 56/95 31 24 24 32 34 21
Combination variable for low MCT1 and high MCT4 histoscore was counted. TNM-staging and grade of differentiation 
was available from 98 patients and tumor size from 95 patients. MCT1 material consisted only of 97 patients due to 
unrepresentative samples. Significant p-values are shown in bold.
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or survival. High cytoplasmic MCT4 intensity and high 
percentage of positive cells correlated significantly 
with distant metastases (intensity P = 0.010; percentage 
P = 0.032) and with high tumor stage (intensity P = 
0.033; percentage P = 0.035). MTCO1 percentage of 
positive cells correlated significantly with poor grade of 
differentiation. 
Stromal expression of MCT1, MCT4 or MTCO1 
showed no correlation with any clinical parameters of 
survival.
DISCUSSION
In this study we characterized MCT1, MCT4 and 
MTCO1 expression in esophageal metaplasia–dysplasia–
adenocarcinoma sequence. Epithelial cytoplasmic MCT- 
and MTCO1 expression linearly increased towards 
dysplasia and adenocarcinoma. Weak cytoplasmic MCT1 
expression and strong MCT4 expression correlated 
to metastases and poor prognosis in esophageal 
adenocarcinoma. 
The Warburg effect has been suggested to be a 
result of metabolic collaboration between cancer cells and 
stroma. Cancer cells form a mitochondrially active region 
while glycolytic stroma shuttles metabolites to cancer 
cell supporting growth and invasion [8, 9–11]. MCTs 
transport high-energy metabolites through cell membrane 
and regulate the pH of the tumor microenvironment [7]. 
Lactate-extruding MCT4 is induced by hypoxia, and is a 
known HIF1-alpha target gene [12, 13] In contrast, MCT1 
transporter facilitates the uptake of lactate [6]. Our data 
shows significant increase of MCT expression (associated 
with higher MTCO1 expression) in Barrett’s dysplasia 
compared to normal epithelium indicating increased 
metabolic activity in these lesions. Stepwise increase in 
metaplasia–dysplasia–adenocarcinoma sequence was 
observed with all studied immunostainings. The mean 
expression of MCT1 and MCT4 decreased from dysplastic 
lesions to adenocarcinoma. These findings suggest that a 
complex metabolic shift occurs during metaplastic and 
dysplastic changes in the esophagus. 
MCT1 has been previously reported to be highly 
expressed in central nervous system, breast, lung, cervix, 
prostate and stomach cancers [14–19]. High MCT4 
expression has been shown to correlate to poor prognosis in 
breast, lung, gastric, colon and prostate cancer [17, 20–22]. 
In this study, low cytoplasmic MCT1 expression and high 
MCT4 expression in cancer cells correlated to advanced 
stages and survival. Furthermore, the cytoplasmic MCT1-/
MCT4+ combination score correlated significantly 
Figure 2: Kaplan-Meier curve showing esophageal adenocarcinoma survival stratified by MCT1 histoscore (A), MCT4 
histoscore (B) and combination of low MCT1 and high MCT4 histoscore (C).
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with distant metastases and tumor stage. Mitochondrial 
energy metabolism is altered in metaplasia-dysplasia-
adenocarcinoma sequence. Oxidative phosphorylation 
profiles might predict progression of Barrett’s esophagus 
to adenocarcinoma [5]. MTCO1 is a core component in 
cytochrome c oxidase, which is terminal enzyme of the 
respiratory electron transport chain of mitochondria [23]. 
We showed that expression increased during esophageal 
adenocarcinoma carcinogenesis with the highest MTCO1 
expression in adenocarcinoma indicating increased 
activity of aerobic mitochondrial energy metabolism. Our 
data suggests that metabolic profile is altered in Barrett’s 
esophagus and esophageal adenocarcinoma. However, 
MTCO1 expression did not correlate to clinical outcome. 
Similar changes in mitochondrial energy metabolism 
have been previously reported in for example prostate, 
neck/head and breast cancers but in these cancers, the 
changes were associated with poor prognosis [8–10, 24]. 
There are also opposite findings, for example in renal cell 
carcinoma [25].
Our findings do not fit in to the theory of “metabolic 
coupling”, but there are other models of lactate shuttle in 
cancer [7]. Our data suggests that lactate is shuttled out 
from cancer cells for controlling pH and as a signaling 
molecule to support for instance cell migration and tumor 
angiogenesis [7]. Our observation is also supported by a 
report of increased activity of carbonic anhydrase IX in 
esophageal adenocarcinoma and its correlation to poor 
survival. This indicates important role of pH control in 
esophageal adenocarcinoma [26]. Gram-negative bacteria 
tolerate acidic environments [27] and bacterial flora 
undergoes a shift towards more gram-negative flora in 
Barrett’s esophagus [28, 29]. This might be related to 
lactate metabolism. However, with the strong causal 
relationship between acid reflux and Barrett’s esophagus, 
the relationship is likely complex.
Strength of the current study is that the treatment 
of all esophageal cancer patients in Northern Finland is 
centralized solely to Oulu University Hospital, making our 
study less prone to selection bias. Interobserver agreement 
was excellent with no required consensus statements, 
indicating fluent repeatability of the evaluation. Use of 
only immunohistochemistry is a possible weakness. The 
immunohistochemical analysis was validated via dual 
negative controls and tested for the effect of the age of the 
paraffin blocks.  We tested the markers for field-effect by 
comparing the expression levels in normal, metaplastic and 
dysplastic epithelium between adenocarcinoma and dysplasia 
patients [30]. There were no indication for such effect 
for MCT4 and MTCO1. MCT1 expression was higher in 
patients with esophageal adenocarcinoma compared to those 
with dysplasia as the most advanced diagnosis, suggesting 
a possible field-effect by cancer. However, the expression 
of MCT1 similarly increased during metaplasia-dysplasia 
sequence in both groups. The observed possible field-effect 
thus does not bias the interpretation of the study results.
In conclusion, the expression of MCT1, MCT4 
and MTCO1 increase from Barrett’s esophagus to 
dysplasia indicating metabolic alteration during dysplastic 
progression. Low cytoplasmic expression of MCT1 and 
high expression of MCT4 associate with advanced stage 
and poor prognosis in esophageal adenocarcinoma.
MATERIALS AND METHODS
Patients
The use of patient samples and the data inquiry 
were approved by the Oulu University Hospital Ethics 
Committee. The need to obtain a written or oral consent 
from the patients for using the samples in research was 
waived by the Finnish National Authority for Medicolegal 
Affairs (VALVIRA, Dnro 10832/06.01.03.01/2014)
Paraffin-embedded, archival specimens of 
esophageal adenocarcinoma or esophageal dysplasia 
were obtained from the Department of Pathology, Oulu 
University Hospital, between the years 1987–2013. The 
final series consisted of 99 patients with esophageal 
adenocarcinoma, 10 with high-grade dysplasia, and 20 
with low-grade dysplasia as the most advanced lesion. 
The specimens with carcinoma or dysplasia contained 
a selection of other tissues and lesions, such as normal 
esophageal mucosa, gastric or intestinal metaplasia and 
less advanced dysplasia, these being present in either 
the same tissue block or additional tissue blocks. The 
material has been earlier described elsewhere [31, 32]. 
The median age of the cancer patients was 64 years 
(range 43–90). The median follow-up time was 36 months 
(range 0–288 months) for the surviving patients. The 
patient survival data was acquired from Statistics Finland. 
TNM-staging and grade of differentiation was available 
from 98 patients and tumor size from 95 patients. MCT1 
immunohistochemical material consisted only of 97 
adenocarcinoma samples due to unrepresentative samples.
Immunohistochemistry
Immunohistochemistry was performed on the 
tissue block sections, which were first selected by 
expert gastrointestinal pathologist, on the basis of 
hematoxylin and eosin-staining, to be representative 
for the tumor mass in the resected specimen. Dako 
Envision kit (Dako, Copenhagen, Denmark) was used 
for immunohistochemical with a high temperature 
antigen retrieval in citrate buffer for 15 minutes. 
Diaminiobenzidine (Dako basic DAB-kit) was used as a 
chromogen. All staining was done with Dako Autostainer 
(Dako, Copenhagen, Denmark). Immunostaining was 
performed with a commercial antibody MCT1; sc-50324, 
rabbit polyclonal IgG, lot I2710, dilution 1:100, MCT4; 
sc-50329, rabbit polyclonal IgG, lot A3113 dilution 
1:500, Santa Cruz Biotechnology, Dallas, Texas, US 
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and MTCO1; ab14705, mouse monoclonal IgG2a, lot 
GR94203-16, dilution 1:100, Abcam, Cambridge, UK
We validated the immunohistochemical analysis two 
series of negative controls (omitting the primary antibody 
and by replacing primary antibody with the mouse 
primary antibody isotype control). To confirm the antigen 
preservation in the old paraffin blocks we compared the 
MCT1, 4 and MTCO1 staining intensities in esophageal 
adenocarcinoma between old and new blocks divided by 
the median age of the blocks. No significant differences 
were found. 
Assessment of immunostaining
The hematoxylin and eosin-staining sample 
slides were digitized using Aperio AT2 Console, 
Leica Biosystems Imaging Inc, Nussloch, Germany 
for identification and marking of different lesions 
in the specimens. Identification was made an expert 
gastrointestinal pathologist (T.J.K.). Immunoreactivity of 
MCT1, 4 and MTCO1 was analyzed by two independent 
researchers (H.H and O.H) who were blinded from the 
clinical data, using method described earlier. We assessed 
the intensity of staining (0–3), the percentage of positive 
cells (0–100), the percentage of nuclear and membrane 
positive cells (0–100) [31, 32]. Tumor stromal staining 
pattern assessed as 0, no detectable staining; 1, focal 
staining; 2, areas diffuse staining present in less than 
half of stromal area; 3, expression of moderate density 
distributed in more than half but not in all parts of the 
tumor stroma; 4, dense expression extending throughout 
the stroma as previously described [8]. All evaluated 
parameters were assessed in normal esophageal squamous 
epithelium, gastric and intestinal metaplasia, low- and 
high-grade dysplasia and adenocarcinoma. Mean values 
of two independent estimates were used if there was 
no difference over 1 in the intensity or over 30% in 
the percentage. If the difference was more extensive, 
consensus was reached after re-evaluation with a third 
researcher (T.J.K). Evaluation did not differ as cross-
borders was set and for that re-evaluation not needed. 
Mean intensity and mean percentage was then multiplied 
together to obtain a histoscore (0–300). Histoscore was 
dichotomized into equally sized groups by the median 
value of MCT1, MCT4 and MTCO1 histoscore as 
previously described [33, 34]. 
Statistical analysis
We used IBM SPSS Statistics 22.0 (IBM corp., 
Armonk, NY) for statistical analyses. To compare 
immunostainings expression between different lesions 
we used one way ANOVA with Tukey in post hoc 
analysis was used. Independent sample T-test was used 
to compare histoscores between carcinoma patients 
(n = 99) and patients with dysplasia (n = 30, HGD and 
LGD combined) to evaluate possible field-effect of 
adjacent adenocarcinoma. The chi-square-test was used 
to calculate statistically significant differences between 
prognostic and clinicopathologic variables. Life tables 
were calculated according to the Kaplan-Meier method, 
and the survival curves were compared using the log-
rank test. Cox proportional hazards model with backward 
selection was used for multivariate analysis with following 
covariates: Age, gender, T-stage, N-stage, M-stage and 
grade of differentiation. 
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